Hypertension Trial, Recruiting NCT06938516 Sponsor: A.Menarini Asia-Pacific Holdings Pte Ltd Condition: Hypertension
Back to Hypertension

Hypertension Trial, Recruiting

NCT06938516
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who have either newly diagnosed or uncontrolled high blood pressure (with specific blood pressure readings recorded at a screening appointment), as defined by 2018 European heart guidelines.
  • People with high blood pressure — with or without other heart or blood vessel conditions (such as coronary artery disease, heart failure, peripheral artery disease, stroke-related conditions, irregular heart rhythms, or valve problems) — who have recently been prescribed or are already taking a medication called Nebilet, as long as they have been taking it for no more than 2 weeks at the time of screening.
  • People with high blood pressure who are willing to give their consent to take part in the study.
  • Women of childbearing age who are willing to use a reliable method of contraception during the study.

Who may not be able to join:

  • People who have had a serious heart or blood vessel event (such as a heart attack or stroke) within the last 3 months.
  • People with severe heart failure classified as the most serious category (Class IV) under a standard medical grading system (confirm with trial site).
  • People for whom Nebilet is not considered medically appropriate, or where the treating doctor believes participation could be unsafe or interfere with the ability to complete the study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Dr Radhika Mehta, A. Menarini Asia-Pacific Holding Pte Ltd

Phone: +65-93885069

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
A.Menarini Asia-Pacific Holdings Pte Ltd
Registry
ClinicalTrials.gov
Start date
20 December 2023
Est. completion
30 November 2028

Where this trial is recruiting

🇮🇩 Indonesia 🇲🇾 Malaysia 🇵🇭 Philippines 🇰🇷 South Korea 🇹🇼 Taiwan 🇹🇭 Thailand 🇻🇳 Vietnam

Primary endpoints

Change in mean sitting systolic blood pressure from baseline to one year of treatment in hypertensive patients on Nebilet based treatment.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov